



## Transient Receptor Potential (TRP) Channels as Novel Therapeutic Targets

Guest Editor:

**Dr. Dana Cucu**

Faculty of Biology, University of  
Bucharest, 050095 Bucharest,  
Romania

Deadline for manuscript  
submissions:

**closed (20 July 2024)**

### Message from the Guest Editor

The discovery of a transient receptor potential (TRP) channel in 1969 as a sensor for phototransduction in *Drosophila melanogaster* began an era of intensive research, leading to the identification of the TRP superfamily comprising 28 cation-permeable channels. This knowledge and technical developments have brought us to the point where we can identify TRP channels as chemical and cellular sensors. It may be the moment that we propose some ways to use these poly-modal channels, as well as their agonists and antagonists, for therapy. However, before our knowledge in the field breaks the barrier from bench to bedside, we still need to answer some questions. We do not know, for instance, the signalling pathways in which TRP channels stimulate or inhibit cell migration, cell proliferation or other tumoral processes. Is this related only to the transport of  $Ca^{2+}$ , as we are tempted to believe? Or are there other features independent of the channel conductance? For these and many other questions, we want to search for answers in this Special Issue, "Transient Receptor Potential Channels as Novel Therapeutic Targets".





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)